Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
复制标题
达卡巴嗪和门诊白细胞介素 2 治疗转移性恶性黑色素瘤：西南肿瘤组 II 期试验。
DOI：
10.1093/jnci/84.11.893
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Sondak,VK
中科院分区：
文献类型：
--
作者：
Flaherty,LE;Liu,PY;Fletcher,WS;Goodwin,JW;Balcerzak,SP;Daniels,D;Stephens,RL;Sondak,VK
0（0）13（100）可评估毒性和反应。1例患者因缺乏IV期疾病的记录而不合格。一名登记的患者从未接受过治疗。14例接受治疗的患者中有12例在诊断为转移性疾病后4周内开始治疗。有1例治疗相关死亡。该患者在第三次给予IL-2后4.5小时发生突发室上性心动过速，变得兴奋，尽管他的血压对多巴胺迅速反应，但没有
0 (0) 13 (100) assessable for toxicity and response. One patient was ineligible because of a lack of documentation of stage IV disease. One registered patient was never treated. Twelve of 14 treated patients began treatment within 4 weeks of diagnosis of metastatic disease. There was one treatment-related death. This patient developed sudden supraventricular tachycardia 4.5 hours after his third dose of IL-2, became hypotensive, and, despite a prompt response of his blood pressure to dopamine, did not